The biopharmaceutical market has great potential for development, and a large number of companies are deploying in this field

Recently, it was reported that Ganli Pharmaceutical announced that it would participate in the D round of investment in Saifen Technology, a leading company in the field of chromatographic separation technology in China, but the relevant amount was not disclosed
.
From the perspective of industry insiders, as one of the leading domestic insulin companies, Ganli Pharmaceutical's investment in Saifen Technology is a new exploration in deepening the layout of the biopharmaceutical industry chain
.
At the same time, this strategic investment will also help Ganli Pharmaceutical to integrate Saifen Technology's advantages in purification chromatography technology, feed back its product research and development technology, and create more industrial value
.
A large number of companies are deploying in the biopharmaceutical field (picture source: Pharmaceutical Network) A large number of companies are deploying in the biopharmaceutical field.
It is worth noting that in recent years, with the continuous acceleration of the development of biopharmaceutical technology, a large number of companies have become more and more potential for market development.
All are beginning to accelerate the layout of this field
.
It is reported that in August this year, Chutian Technology established a holding subsidiary, Chutian Siyoute, which specializes in the production and sales of biopharmaceutical disposable technology products, such as bioreactor disposable bags, liquid dispensing bags, liquid storage bags, breathing bags and Its membrane material
.
In September, the company also established a holding subsidiary, Chutian Microsphere, which has already successfully developed a number of product laboratories
.
For Chutian Technology's series of actions, industry analysts believe that it is the epitome of the gradual expansion of Chutian Technology into its related fields with pharmaceutical equipment as the cornerstone
.
From the current point of view, the biopharmaceutical technology product business has clearly become the company's key development target
.
It is expected that with the deepening of the preliminary layout, Chutian Technology is expected to usher in the harvest period of some products next year
.
Coincidentally, in addition to Chutian Technology, Canaan Technology is also planning to focus on the development of pharmaceutical liquid dispensing systems, intelligent logistics systems and pharmaceutical R&D services for bio-innovative drugs
.
Not long ago, Canaan Technology also publicly stated that the rapid development of the biopharmaceutical industry will bring more business opportunities to the company
.
In addition, on October 14th, Tofflon invested nearly 500 million yuan in the pharmaceutical system equipment production base construction project has also signed the Shanghai Jinshan Industrial Zone.
It is reported that the project will build a high-end, intelligent, and digital advanced manufacturing platform.
Professional technical services for the development of the biomedical industry
.
Domestic pharmaceutical equipment needs to accelerate high-end market competitiveness.
According to Frost & Sullivan’s prediction, the scale of China’s biopharmaceutical market will rapidly expand at an average compound annual growth rate of 18% in the next few years, and reach 59 billion yuan in 2030
.
Therefore, based on the huge market prospects, in addition to the above companies, it is expected that a large number of companies will also accelerate their entry into the biopharmaceutical field
.
But on the whole, the enthusiasm of pharmaceutical equipment giants will be even higher
.
In this regard, the industry believes that with the rapid rise of China's biopharmaceutical industry in the future, relevant pharmaceutical equipment companies are expected to usher in more opportunities
.
But it is worth noting that with the introduction of AI technology and the popularization of Industry 4.
0 in the biopharmaceutical industry, the biopharmaceutical industry will also enter a new round of upgrading
.
Affected by this, the demand for more advanced and higher-end pharmaceutical equipment will continue to expand
.
In this context, the industry has proposed that the pharmaceutical industry needs to accelerate its transformation and upgrading, and increase its deployment in the high-end pharmaceutical equipment market
.
In fact, at present, many domestic pharmaceutical equipment companies have already begun to innovate and upgrade biopharmaceutical production equipment, and strive to obtain a greater improvement in the stability and safety of the equipment to meet the higher demands of the market
.
If any company has been committed to promoting the continuous production and intelligent manufacturing of biopharmaceuticals, its innovatively developed key biopharmaceutical equipment (bioreactors, bioengineering liquid dosing modules) and intelligent production platform (Bio-PAS) have been able to greatly Improve production efficiency and safety
.
However, in general, China's biopharmaceutical equipment industry still has serious shortages in the high-end market, and the overall innovation capability of the industry is still relatively weak
.
Therefore, while domestic pharmaceutical equipment companies see opportunities, they also need to continue to increase R&D investment to continuously meet the more and higher demands of pharmaceutical companies and help China’s biopharmaceutical industry to develop in a higher-quality direction.
And accelerate the breaking of import monopoly and realize the substitution of imported products
.